Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

By Murata R.   Overgaard J.   Horsman M. R.  

International Journal of Hyperthermia, Vol. 17, Iss. 6, 2001-11 ,pp. : 508-519

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

By Jameson M.   Baguley B.   Kestell P.   Zhao L.   Paxton J.   Thompson P.   Waller S.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor

By Philpott M.   Ching L.-M.   Baguley B.C.  

European Journal of Cancer, Vol. 37, Iss. 15, 2001-10 ,pp. : 1930-1937

Elsevier

Access to resources Recommend Favorite

NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Woon S.-T.   Zwain S.   Schooltink M.A.   Newth A.L.   Baguley B.C.   Ching L.-M.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1176-1183

Elsevier

Access to resources Recommend Favorite

Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor

By Chung Francisco   Wang Liang-Chuan   Kestell Philip   Baguley Bruce   Ching Lai-Ming  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 5, 2004-05 ,pp. : 377-383

Springer Publishing Company

Access to resources Recommend Favorite